Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Berenson is the founder and Principal for the Berenson Cancer Center, a unique multi-faceted business entity built around an established and integrated healthcare and biotech family of companies. These consist of the Berenson Cancer Center, a prolific specialty practice in West Hollywood, CA focused on the treatment of patients with multiple myeloma and related malignancies and conditions; ONCOtherapeutic, a recognized targeted CRO leading preclinical research and clinical trials from phase I to IV in community and academic oncology sites throughout the US; and ONCOtracker, a preclinical CRO and emerging incubator for cancer treatment management innovation focused on the diagnosis, monitoring and treatment of multiple myeloma, other B-cell malignancies and related disorders in pursuit of intellectual property supporting treatment progress & improved outcomes.
Dr. Berenson also founded the Institute for Myeloma & Bone Cancer Research (IMBCR) in 2003 and serves as its Medical and Scientific Director: A mission-driven 501(C)3 non-profit institute committed to advance the monitoring and treatment of multiple myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care. IMBCR is dedicated to making the impossible possible so that all patients with myeloma live their best life.
Dr. Berenson has authored nearly 300 peer-reviewed publications and contributed to multiple book chapters. He has served as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section and is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. Dr. Berenson has also served on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society.